In order to stay on the market, vaping and other electronic nicotine delivery system (ENDS) product manufacturers must submit a PMTA by Wednesday, September 9. Panelists will provide multiple perspectives on the PMTA process, including whether it is an appropriate safeguard of public health or creates a barrier to entry that stifles competition. Panelists will also discuss FDA’s pending review of these applications, including how it may use its enforcement discretion after September 9, how it will apply the public health standard in light of youth and population-wide risks, and what is needed to make the process appropriately efficient and transparent.

Get Access

  • +$100 for nonmembers

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.


Stacey Gagosian, Managing Director, Public Policy, Truth Initiative
Moira Gilchrist, Vice President, Scientific and Public Communications, Phillip Morris International
Matt Holman, Director, Office of Science, Center for Tobacco Products, FDA
Moderated by Stacy Ehrlich, Partner, Kleinfeld, Kaplan & Becker LLP

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.


On-demand content can be played back on most devices.


CLE credit is not currently available for pre-recorded sessions.

Related Content